Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Plasma cell 1

Conditions

Sarcoma 142Osteosarcoma 26Liposarcoma 25Leiomyosarcoma 25Histiocytoma, Malignant Fibrous 19Hemangiosarcoma 18Sarcoma, Synovial 17Neurofibrosarcoma 17Fibrosarcoma 17Rhabdomyosarcoma 16Dendritic Cell Sarcoma, Interdigitating 16Sarcoma, Ewing 13Neuroectodermal Tumors, Primitive, Peripheral 11HIV Infections 11Sarcoma, Kaposi 10Neoplasms 10Neoplasm Metastasis 10Malignant mesenchymal tumor 10Acquired Immunodeficiency Syndrome 10Lymphoma, Large B-Cell, Diffuse 9Dermatofibrosarcoma 9Ovarian Neoplasms 8Lymphoma 8Hemangiopericytoma, Malignant 8Desmoplastic Small Round Cell Tumor 8Sarcoma, Alveolar Soft Part 6Chondrosarcoma, Extraskeletal Myxoid 6Bone Neoplasms 6Chondrosarcoma 5Burkitt Lymphoma 5

Interventions

seclidemstat 2Topotecan 2Cyclophosphamide 2selinexor 1pazopanib 1Zoledronic Acid 1Proton Therapy 1Ifosfamide 1Doxorubicin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Myoepithelioma × Doxorubicin × Sarcoma × Clear all
NCT06239272 2026-05-19

NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)

St. Jude Children's Research Hospital

Phase 1/2 Recruiting
139 enrolled
Plasma cellSarcoma

Histiocytoma, Angiomatoid Fibrous, Chondrosarcoma, Extraskeletal Myxoid, Fibrosarcoma, Glomus Tumor, Granuloma, Plasma Cell, Hemangiosarcoma, Liposarcoma, Myoepithelioma, Sarcoma, Osteosarcoma, Disorders of Sex Development, Granular Cell Tumor, Neoplasms, Adipose Tissue, Liposarcoma, Myxoid, Dermatofibrosarcoma, Sarcoma, Clear Cell, Smooth Muscle Tumor, Nerve Sheath Neoplasms, Neurofibrosarcoma, Hemangioendothelioma, Epithelioid, Vascular Neoplasms, Solitary Fibrous Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡